Oracle Corporation (NYSE: ORCL) topped revenue and earnings forecasts for the third quarter of 2020, allowing the stock to gain 3.7% in aftermarket hours on Thursday.
Total revenues rose 2% year-over-year to $9.8 billion, surpassing estimates of $9.7 billion. Revenues were up 3% in constant currency.

GAAP net income fell 6% to $2.6 billion while GAAP EPS rose 4% to $0.79. Adjusted net income was $3.2 billion while adjusted EPS grew 11% to $0.97, beating forecasts of $0.96.
Short-term deferred revenues were $7.8 billion. Fusion ERP Cloud revenues were up 37% year-over-year on a reported basis and 38% in constant currency.
Subscription revenues were $6.9 billion, up 4% on a reported basis and 5% in constant currency. Subscription revenues now account for the majority of the company’s revenues. Cloud License and On-Premise License revenues were $1.2 billion, down 2% on a reported basis and flat on a constant currency basis. Hardware and Services revenues both saw decreases compared to the prior-year period.
For the fourth quarter, Oracle expects total subscription revenues to range between 3-5% in both constant currency and US dollars. Total revenues are expected to range between negative 2% to positive 2% in both constant currency and US dollars. Adjusted EPS is expected to grow 3-9% to a range of $1.20-1.28 in both constant currency and US dollars.
The Board of Directors declared a quarterly cash dividend of $0.24 per common share, payable to stockholders of record as of April 9, 2020, with a payment date of April 23, 2020. The company also increased its share repurchase authorization by $15 billion.
Oracle’s shares have fallen 24% over the past one year and 28% in the past one month.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
AVGO Earnings: Broadcom reports higher Q4 FY25 revenue, profit; results beat
Semiconductor company Broadcom, Inc. (NASDAQ: AVGO) on Thursday reported an increase in revenue and adjusted earnings for the fourth quarter of fiscal 2025. The numbers also surpassed analysts' expectations. Adjusted
Unicycive is all-in on kidney care, focusing on underserved areas: CEO
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a biotech firm engaged in the development of novel treatment options for patients with renal diseases. In an email interview with AlphaStreet, CEO Dr.
Lamb Weston (LW) is set to report Q2 2026 earnings next week, here’s what to look for
Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose over 1% on Thursday. The stock has gained 4% over the past three months. The French fry giant is slated to